Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01560884 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb
A Phase 1 study of Safety and Phosphate Binding Capacity, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT01560884 is a Phase 1 study of Safety and Phosphate Binding Capacity that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 32 participants, below the 125-participant average among 10 other Safety trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01560884, a Phase 1 study of Safety and Phosphate Binding Capacity, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this trial is to study safety, tolerability, and phosphate binding capacity of Renazorb (SPI-014) in healthy volunteers before conducting trials in patients with renal failure. Renal excretion of phosphate is expected to decrease and fecal excretion of phosphate is expected to increase after treatment.
Conditions Studied
Interventions
- DRUG Renazorb 1500 mg/day
- DRUG Renazorb 3000 mg/day
- DRUG Renazorb 4500 mg/day
- DRUG Renazorb 6000 mg/day
Study Locations (1)
Maryland
- PAREXEL International - Baltimore Early Phase Clinical Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01560884
The ClinicalTrials.gov registry entry for NCT01560884 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 10 other Safety trials with a reported enrollment target (74% lower). The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Safety appearing as the primary indexed condition, and to 4 interventions - of which Renazorb 1500 mg/day is the first listed.
NCT01560884 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01560884 about?
NCT01560884 is a clinical study titled "Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb". The purpose of this trial is to study safety, tolerability, and phosphate binding capacity of Renazorb (SPI-014) in healthy volunteers before conducting trials in patients with renal failure. Renal excretion of phosphate is expected to decrease and fecal excretion of phosphate is expected to increas...
What is the current status of trial NCT01560884?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2012-04. Estimated completion is 2012-09.
What conditions does trial NCT01560884 study?
This clinical trial studies the following conditions: Safety, Phosphate Binding Capacity.
What interventions are being tested in trial NCT01560884?
The interventions under investigation include: Renazorb 1500 mg/day (DRUG), Renazorb 3000 mg/day (DRUG), Renazorb 4500 mg/day (DRUG), Renazorb 6000 mg/day (DRUG).
Who is sponsoring clinical trial NCT01560884?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01560884 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Safety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Curcumin and Retinal Study
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience
COMPLETED · Phase 1
-
Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects
COMPLETED · Phase 1
-
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.